You are here: Industry Insights > I-Mab Biopharma

News List

I-Mab Explores TJM2 in Treating Severe COVID-19 Disease contractpharma
March 16, 2020
Clinical study will explore the potential of TJM2, a mAb against Cytokine Release Syndrome, which is an overreaction of the immune system caused by inflammation.
I-Mab to Develop TJM2 for Cytokine Release Syndrome Patients with COVID-19 americanpharmaceuticalreview
March 16, 2020
I-Mab Biopharma is initiating the development of TJM2 (TJ003234) to treat cytokine storm in severe and critically ill patients caused by the coronavirus disease (COVID-19).
I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China prnasia
January 05, 2020
I-Mab initiated two registrational trials with TJ202/MOR202 in relapsed or refractory MM in Taiwan, China in early 2019 and expanded these trials into mainland China in late 2019, after receiving IND clearance from the National Medical Products Administra
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors prnasia
August 06, 2019
I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases ...
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs pharmafocusasia
April 19, 2019
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
I-Mab Biopharma collaborates with Roche for combination therapy biospectrumasia
April 11, 2019
I-Mab Biopharma (I-Mab), a clinical stage biopharmaceutical company exclusively focused on the development of ……
I-Mab, Jiangsu Nhwa team up with Biodextris, Brigham for treating neuro disorders biospectrumasia
April 11, 2019
I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on^
I-Mab Biopharma gets USFDA IND nod for antibody TJD5 biospectrumasia
January 24, 2019
China-based clinical stage biopharmaceutical company, I-Mab Biopharma, exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases...
I-Mab Biopharma Receives FDA IND Clearance for Proprietary CD73 Antibody TJD5 americanpharmaceuticalreview
January 23, 2019
I-Mab Biopharma announced the Investigational New Drug (IND) application for the initiation of a Phase 1 clinical study for TJD5 in patients with advanced solid tumor has cleared the required 30 day review by the U.S. Food and Drug Administration (FDA)...
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy pharmafocusasia
November 05, 2018
I-MAB Biopharma Co., Ltd., a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune diseases...

Previous page 1 2 Next page